Search Results

You are looking at 91 - 100 of 786 items for :

  • "risk factor" x
  • Refine by Access: All x
Clear All
Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas, and Catherine H. Van Poznak

effects on bone metabolism. The hormone deprivation state resulting from certain cancer therapies enhances osteoclastic bone resorption, promoting bone loss. Osteoporosis risk factors unique to patients with cancer include chemotherapy-induced menopause

Full access

John Charlson, Elizabeth C. Smith, Alicia J. Smallwood, Purushottam W. Laud, and Joan M. Neuner

along with other risk factors for fracture. 3 , 5 – 8 Although a few studies early in the use of AIs suggested that adherence to these guidelines was suboptimal, 9 – 13 there are few recent data. As consensus about the importance of AIs in HT regimens

Full access

Jeffrey Crawford, David C. Dale, Nicole M. Kuderer, Eva Culakova, Marek S. Poniewierski, Debra Wolff, and Gary H. Lyman

2005 ; 23 : 569 – 575 . 16. Lyman GH Lyman CH Agboola O . Risk models for predicting chemotherapy-induced neutropenia . Oncologist 2005 ; 10 : 427 – 437 . 17. Gomez H Hidalgo M Casanova L . Risk factors for treatment

Full access

Pilar de la Morena Barrio, María Ángeles Vicente Conesa, Enrique González-Billalabeitia, Edgar Urrego, Elisa García-Garre, Elena García-Martínez, Marta Zafra Poves, Vicente Vicente, and Francisco Ayala de la Peña

have DM. 14 , 15 Because DM is itself a cause of peripheral neuropathy, PIPN might be more prevalent and severe in patients with breast cancer and DM. However, the available evidence is limited for considering DM a risk factor for PIPN. Several case

Full access

Mathias Kvist Mejdahl, Birgitte Goldschmidt Mertz, Pernille Envold Bidstrup, and Kenneth Geving Andersen

Identify psychological risk factors for PPBCT that may be targeted in preventive interventions Background Persistent pain after breast cancer treatment (PPBCT) affects 25% to 60% of patients treated for breast cancer, 1 may persist for

Full access

Monira Alwhaibi, Usha Sambamoorthi, Suresh Madhavan, Thomas Bias, Kimberly Kelly, and James Walkup

). These dimensions are an individual's physical make-up, social support, access to care, health behaviors, psychological factors, biological risk factors, treatment factors, community resources, and geographic region. Methods Data Source SEER

Full access

Arjun Gupta, Raseen Tariq, Ryan D. Frank, Gary W. Jean, Muhammad S. Beg, Darrell S. Pardi, David H. Johnson, and Sahil Khanna

, prevention strategies, and newer treatment modalities for CDI. 4 – 9 Patients with cancer are particularly vulnerable to CDI, which is attributed to traditional risk factors such as age; cancer itself; hospitalization and health care exposure; chemotherapy

Full access

Cocav A. Engman and Leo R. Zacharski

responsible for the content and editorial decisions regarding this manuscript. References 1. Heit JA Silverstein MD Mohr DN . Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study . Arch Intern

Full access

Francis P. Worden and Huan Ha

risk factor for the increase in incidence of tonsillar cancer . Int J Cancer 2006 ; 119 : 2620 – 2623 . 9. D'Souza G Kreimer AR Viscidi R . Case-control study of human papillomavirus and oropharyngeal cancer . N Engl J Med 2007 ; 356

Full access

Scott Cooper, Mohammed Zaher, and Gregory Diorio

.S. Surveillance, Epidemiology, and End Results registry (SEER). Clinical identification of risk factors for adverse outcomes will allow for patient-specific counseling on prognosis and intervention. Methods: Population-based data from SEER 18 was used to assess